Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-7172 combination therapy in RAS-altered advanced pancreatic cancer
CTR20263427Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-7172 in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Started Sep 2026; status: active.
02
Drugs
HRS-7172
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20263427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263427.